Cancer Research Institute collaboration with the Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb, and Apexigen will test CD40 antibody APX005M, nivolumab, and chemotherapy in pancreatic cancer patients.
First-of-its kind campaign to fund promising immunotherapy research in Israel, a global leader in cancer research
Fight Colorectal Cancer and the Cancer Research Institute announce the recipient of their jointly-funded $400k grant to support immunotherapy research in metastatic colorectal cancer.
CRI's largest grant to a single investigator will support development of microchip-based research models of cancer and the immune system
The Focused Ultrasound Foundation (FUSF) and the Cancer Research Institute (CRI) are establishing a partnership with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation
We introduce you to Thomas Hudson, M.D., vice president, head of oncology discovery and early development at AbbVie.